2. Metabolic Enzyme/Protease Apoptosis
  3. MMP Apoptosis
  4. Edaravone

Edaravone  (Synonyms: MCI-186)

Cat. No.: HY-B0099 Purity: 99.83%
COA Handling Instructions

Edaravone is a strong novel free radical scavenger, and inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.

For research use only. We do not sell to patients.

Edaravone Chemical Structure

Edaravone Chemical Structure

CAS No. : 89-25-8

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 61 In-stock
Solution
10 mM * 1 mL in DMSO USD 61 In-stock
Solid
500 mg USD 55 In-stock
5 g USD 66 In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 19 publication(s) in Google Scholar

Other Forms of Edaravone:

Edaravone Related Antibodies

Top Publications Citing Use of Products

    Edaravone purchased from MedChemExpress. Usage Cited in: Int Wound J. 2023 Apr 11.  [Abstract]

    Edaravone (EDA; 20.0 mg/kg/day; i.p.; 7 days) significantly promotes VEGF and MMP9 expression in mice.

    Edaravone purchased from MedChemExpress. Usage Cited in: Int Wound J. 2023 Apr 11.  [Abstract]

    Edaravone (EDA; 20.0 mg/kg/day; i.p.; 7 days) significantly reduces the number of apoptotic cells in mice.

    Edaravone purchased from MedChemExpress. Usage Cited in: Int Wound J. 2023 Apr 11.  [Abstract]

    Edaravone (EDA; 20.0 mg/kg/day; i.p.; 7 days) significantly increases the protein expression of TGF-β1, VEGF and MMP9 in mice.

    Edaravone purchased from MedChemExpress. Usage Cited in: Front Physiol. 2020 Jan 15;10:1596.

    A) HE staining of muscle tissue after artery ligation shows that the cells are round, and reveals infiltration of inflammatory cells in both control (Con) and ob/ob (Ob) mice. (B) MyoD immunostaining is lower in Ob than Con at 7 days after ligation of the femoral artery. However, pretreatment with Edaravone increases the expression of MyoD in obese mice.

    Edaravone purchased from MedChemExpress. Usage Cited in: Front Physiol. 2020 Jan 15;10:1596.

    TNF-α expression is significantly increased by treating C2C12 cells with 250 µM H2O2. In addition, pretreatment with edaravone at 100 µM, TNF-α expression is significantly suppressed (∗ compared with 0 µM H2O2, p < 0.01; # compared with 250 µM H2O2, p < 0.01).

    Edaravone purchased from MedChemExpress. Usage Cited in: Front Physiol. 2020 Jan 15;10:1596.

    After treating C2C12 cells with 250 µM H2O2, viability is significantly decreased, and improvement in survival rate was observed in the group treated with Edaravone at 100 µM (∗compared with 0 µM H2O2, p < 0.01; # compared with 250 µM H2O2, p < 0.01).

    View All MMP Isoform Specific Products:

    View All Isoforms
    MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Edaravone is a strong novel free radical scavenger, and inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.

    In Vitro

    Edaravone performs both preventative and therapeutic effects against toxicity of glutamate. Pretreatment of edaravone reduces the toxicity of glutamate towards SGNs. Edaravone reduces apoptosis and necrosis caused by glutamate. Pretreatment of edaravone (500 μM) reverses these changes to approximately normal levels. The protective effect of edaravone on SGNs against glutamate-induced apoptosis is associated with PI3K/Akt pathway and Bcl-2 protein family[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Edaravone Related Antibodies
    In Vivo

    Edaravone exerts neuroprotective effects by inhibiting endothelial injury and by ameliorating neuronal damage in brain ischemia. Edaravone provides the desirable features of NOS: it increases eNOS (beneficial NOS for rescuing ischemic stroke) and decreases nNOS and iNOS (detrimental NOS). Post-reperfusion brain edema and hemorrhagic events induced by thrombolytic therapy may be reduced by edaravone pretreatment[1]. Edaravone significantly decreases infarct volume, with the average infarct volume in the edaravone-treated rats (227.6 mm3) being significantly lower than that in the control rats (264.0 mm3). Edaravone treatment also decreases the postischemic hemorrhage volumes (53.4 mm3 in edaravone-treated rats vs 176.4 mm3 in controls). In addition, the ratio of hemorrhage volume to infarct volume is lower in the edaravone-treated rats (23.5%) than in the untreated rats (63.2%)[2]. In edaravone (20 mg/kg)-treated rats, astrocyte activity (glial fibrillary acidic protein) and apoptotic cells (caspase-3) are decreased on the corpus callosum, germinal matrix, and cerebral cortex[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    174.20

    Appearance

    Solid

    Formula

    C10H10N2O
    CAS No.
    SMILES

    O=C1N(C2=CC=CC=C2)N=C(C)C1
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (574.05 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 5.7405 mL 28.7026 mL 57.4053 mL
    5 mM 1.1481 mL 5.7405 mL 11.4811 mL
    10 mM 0.5741 mL 2.8703 mL 5.7405 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (14.35 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (14.35 mM); Clear solution

    • 3.

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (14.35 mM); Clear solution

    *All of the co-solvents are available by MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.83%

    COA (253 KB) HNMR (245 KB) RP-HPLC (206 KB) MS (68 KB)

    Handling Instructions (2659 KB)
    References
    Cell Assay
    [4]

    Cell viability is quantified by MTT assay and trypan blue staining. MTT (5 mg/mL, 20 μL) is added to each well and incubated for 4 h at 37°C after the drug treatments. The medium is removed and the cell pellet is dissolved in DMSO. Then, the optical density (OD) values are measured at 570 nm using an ELISA reader.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Edaravone Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    Edaravone89-25-8MCI-186MCI186MCI 186MMPApoptosisMatrix metalloproteinasesInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Edaravone
    Cat. No.:
    HY-B0099
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.